State Street’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $143M | Sell |
4,395,557
-49,873
| -1% | -$1.6M | ﹤0.01% | 1158 |
|
|
2025
Q4 | $156M | Sell |
4,445,430
-68,402
| -2% | -$2.42M | 0.01% | 1093 |
|
|
2025
Q3 | $119M | Buy |
4,513,832
+738,141
| +20% | +$22M | ﹤0.01% | 1246 |
|
|
2025
Q2 | $100M | Sell |
3,775,691
-279,727
| -7% | -$7.36M | ﹤0.01% | 1315 |
|
|
2025
Q1 | $97.9M | Sell |
4,055,418
-870,072
| -18% | -$27.5M | ﹤0.01% | 1278 |
|
|
2024
Q4 | $198M | Buy |
4,925,490
+251,423
| +5% | +$14.3M | 0.01% | 946 |
|
|
2024
Q3 | $296M | Sell |
4,674,067
-448,361
| -9% | -$26.3M | 0.01% | 711 |
|
|
2024
Q2 | $272M | Buy |
5,122,428
+1,795,861
| +54% | +$118M | 0.01% | 707 |
|
|
2024
Q1 | $273M | Sell |
3,326,567
-2,406,423
| -42% | -$107M | 0.01% | 720 |
|
|
2023
Q4 | $107M | Sell |
5,732,990
-678,072
| -11% | -$8.87M | 0.01% | 1252 |
|
|
2023
Q3 | $71M | Buy |
6,411,062
+1,591,686
| +33% | +$22.8M | ﹤0.01% | 1406 |
|
|
2023
Q2 | $78.1M | Sell |
4,819,376
-461,568
| -9% | -$9.67M | ﹤0.01% | 1386 |
|
|
2023
Q1 | $87.9M | Buy |
5,280,944
+5,034,102
| +2,039% | +$52M | 0.01% | 1268 |
|
|
2022
Q4 | $2.32M | Hold |
246,842
| – | – | ﹤0.01% | 3327 |
|
|
2022
Q3 | $671K | Sell |
246,842
-14,200
| -5% | -$46.5K | ﹤0.01% | 3677 |
|
|
2022
Q2 | $754K | Sell |
261,042
-1,096,134
| -81% | -$2.71M | ﹤0.01% | 3694 |
|
|
2022
Q1 | $4.07M | Sell |
1,357,176
-2,768,391
| -67% | -$9.93M | ﹤0.01% | 3281 |
|
|
2021
Q4 | $19M | Buy |
4,125,567
+83,316
| +2% | +$467K | ﹤0.01% | 2509 |
|
|
2021
Q3 | $25.4M | Sell |
4,042,251
-943,709
| -19% | -$5.83M | ﹤0.01% | 2308 |
|
|
2021
Q2 | $29.9M | Sell |
4,985,960
-1,798,484
| -27% | -$10.7M | ﹤0.01% | 2229 |
|
|
2021
Q1 | $42.9M | Buy |
6,784,444
+1,711,888
| +34% | +$12M | ﹤0.01% | 1857 |
|
|
2020
Q4 | $28.6M | Buy |
5,072,556
+14,392
| +0.3% | +$87.2K | ﹤0.01% | 2011 |
|
|
2020
Q3 | $29.4M | Buy |
5,058,164
+781,402
| +18% | +$5.38M | ﹤0.01% | 1807 |
|
|
2020
Q2 | $30.8M | Buy |
4,276,762
+634,812
| +17% | +$4.22M | ﹤0.01% | 1765 |
|
|
2020
Q1 | $17M | Buy |
3,641,950
+31,688
| +0.9% | +$195K | ﹤0.01% | 1945 |
|
|
2019
Q4 | $29M | Sell |
3,610,262
-250,608
| -6% | -$1.83M | ﹤0.01% | 1887 |
|
|
2019
Q3 | $26.6M | Sell |
3,860,870
-3,071,555
| -44% | -$22.8M | ﹤0.01% | 1876 |
|
|
2019
Q2 | $57.5M | Sell |
6,932,425
-295,463
| -4% | -$2.52M | ﹤0.01% | 1391 |
|
|
2019
Q1 | $71.8M | Buy |
7,227,888
+466,403
| +7% | +$3.9M | 0.01% | 1230 |
|
|
2018
Q4 | $51.7M | Buy |
6,761,485
+707,934
| +12% | +$8.46M | ﹤0.01% | 1326 |
|
|
2018
Q3 | $105M | Buy |
6,053,551
+5,321,983
| +727% | +$63.3M | 0.01% | 1042 |
|
|
2018
Q2 | $6.94M | Buy |
731,568
+699,668
| +2,193% | +$4.65M | ﹤0.01% | 2701 |
|
|
2018
Q1 | $140K | Buy |
+31,900
| New | +$176K | ﹤0.01% | 3590 |
|
Other funds holding VKTX
VCM
VPM
State Street's VKTX Position: Q1 2026 in Review
State Street reduced its Viking Therapeutics (VKTX) stake by 1.1% in Q1 2026, selling an estimated $1.6M and leaving 4,395,557 shares worth $143M. The position accounts for ﹤0.01% of the portfolio, ranked #1158.
State Street first reported a position in VKTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $296M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- State Street held 4,395,557 shares of Viking Therapeutics worth $143M as of Q1 2026.
- State Street sold 49,873 Viking Therapeutics shares in Q1 2026, an estimated $1.6M.
- Viking Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1158 holding.
- State Street first reported a position in Viking Therapeutics in Q1 2018 and has held it in 33 quarters since.
- State Street's Viking Therapeutics position peaked at $296M in Q3 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.